Best second-line treatment for high-risk relapsing prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests the best way to treat prostate cancer that has come back after initial treatment (like surgery or radiation) and shows a few spots on a PSMA scan. It compares different salvage treatments, possibly including radiation and hormone therapy, to slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of prostate cancer (adenocarcinoma).
- Your PSA level must be rising after initial treatment (prostate removal or radiation) and meet certain levels: at least 0.2 ng/mL after surgery, or at least 2 ng/mL above the lowest point after radiation, with a quick doubling time (9 months or less).
- You need to have 1 to 5 spots of cancer spread (metastases) seen on a PSMA PET/CT scan, but not more than 5. Lymph node spread is allowed.
- Your testosterone level must be at least 150 ng/dL (normal).
- You must be generally well enough to carry out daily activities (ECOG performance status 0-2) and be 18 years or older.
- You should not have had chemotherapy for prostate cancer before, and any hormone therapy (like ADT) must be limited (no more than 36 months total and stopped at least 9 months before the trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.